Tel：
(86)(21)60969600
Add: Building 28, Lane 588, Tianxiong Road. Shanghai, P. R. China
Recently, the IceMagic™ CryoAblation Catheter (Multi-channel Temperature Sensing Type) (referred to as " IceMagic™ CryoAblation Catheter ") developed by Shanghai MicroPort EP MedTech Co., Ltd. (referred to as "MicroPort EP") successfully completed its first batch of clinical applications.
The IceMagic™ CryoAblation Catheter is the world's first cryoballoon catheter with surface multi-channel temperature sensing function. Its first batch of clinical applications after listing performed outstandingly, with an immediate pulmonary vein isolation (PVI) rate of 100% for all patients, and the treatment effect was remarkable.
The team of Professors Fu Hua and Zeng Rui from West China Hospital of Sichuan University fully verified the excellent performance of this product technology in the treatment of several patients with paroxysmal atrial fibrillation. One of the applications was completed by Professor Cui Kaijun from West China Hospital of Sichuan University. The patient was a 57-year-old female who was admitted to the hospital due to "paroxysmal palpitations and chest tightness for more than 2 years" and was diagnosed with paroxysmal atrial fibrillation by electrocardiogram. Cryoablation was performed using the IceMagic™ CryoAblation Console and the IceMagic™ CryoAblation Catheter.
The patient had no common trunk of pulmonary veins and the branches were relatively regular. The physicians sent the IceMagic™ CryoAblation Catheter to the ostium of the pulmonary vein through the PathBuilder™ Adjustable Guide Sheath Set. The good adaptability of this catheter enabled it to better fit the pulmonary vein antrum. Based on the characteristics of multi-channel temperature sensing on the surface of the balloon, when judging the occlusion of the pulmonary vein, room-temperature normal saline was used instead of contrast agent to evalsuate the occlusion situation of the pulmonary vein according to the temperature change on the surface of the balloon. Then, the occlusion result was verified with contrast agent. The results evalsuated by the two methods were consistent, and cryoablation was initiated after confirming good occlusion. During the expansion of the antrum ablation, the occlusion of the pulmonary vein was in a partially leaked state, and the contact situation between the balloon and the myocardium and the ablation effect could be evalsuated through the surface temperature of the balloon. Each pulmonary vein recorded TTI during the operation. Electrophysiological examination was performed after the operation to verify the immediate isolation effect. No complications occurred during the procedure, and the procedure ended successfully.
Atrial fibrillation is a common arrhythmia in clinical practice, and there are currently more than 20 million atrial fibrillation patients in China. As an innovative technique in the field of atrial fibrillation treatment, cryoablation simplifies the atrial fibrillation catheter ablation with a new treatment concept, innovates the traditional pulmonary vein isolation method of point-by-point radiofrequency ablation into a continuous band-shaped transmural injury, and has clinical application advantages such as shorter procedural time, simpler operation, and shorter learning curve.
The "surface temperature sensing technique " used in the IceMagic™ CryoAblation Catheter is pioneering. Through the surface multi-channel temperature of balloon sensing function, it can not only judge the occlusion state of the pulmonary vein according to the temperature change on the surface of the balloon without radiation, but also obtain the real surface temperature of the balloon and the contacting tissue in real time and monitor the temperature change of the tissue during cryoablation, helping physicians to evalsuate the treatment effect more accurately, which is of positive significance for improving the safety and effectiveness of cryoablation procedure.
At the recent 2024 West China Atrial Fibrillation Week, the 22nd Atrial Fibrillation Forum and other authoritative academic exchange platforms for the diagnosis and treatment of cardiovascular diseases in China, through academic seminars and procedure broadcasts, the innovative design and excellent clinical performance of this product have been highly recognized by the participating experts.
Professor Fu Hua from West China Hospital of Sichuan University stated that the IceMagic™ CryoAblation Catheter provides new possibilities for optimizing the procedural path, exploring new procedural methods, and expanding the scope of indications. At the same time, to a certain extent, with this tool, electrophysiologists can understand and reveal the mechanism of cryoinjury from a new perspective and precisely control the range of injury.
Professor Cui Kaijun from West China Hospital of Sichuan University mentioned that the surface multi-channel temperature sensing function of the IceMagic™ CryoAblation Catheter can effectively reduce the usage of contrast agent and radiation dose.
Professor Hu Hongde from West China Hospital of Sichuan University believes that the good compliance of the cryoballoon and its high fit to the pulmonary vein make the cryoablation efficiency and pulmonary vein isolation effect better.
Professor Zhou Wei from the Affiliated Hospital of Guizhou Medical University stated that cryoablation technology has obvious advantages in the treatment of elderly patients and patients with poor cardiac function, and can reduce post- procedural complications.
Professor Du Hua'an from the University Town Hospital affiliated to Chongqing Medical University commented that the surface temperature sensing cryoablation technique can provide a more intuitive judgment of the occlusion state and reduce the uncertainty during the procedure. Professor Ou Dengke from Chengdu Fifth People's Hospital pointed out that the application of surface temperature sensingtechnique in cryoablation helps to improve the success rate of the procedure. The catheter has stable performance in cooling and rewarming during the procedure, and the temperature control technology improves the safety and efficiency of the procedure.
In the future, MicroPort EP will continue to be committed to the research and development and application of innovative technologies, promote the development of domestic electrophysiological treatment technologies, provide patients and doctors with more complete products and professional services, and provide electrophysiological interventional diagnosis and treatment integrated solutions with global competitiveness.
